One of the 14 different drugs known to be metabolized to methamphetamine and/or amphetamine is famprofazone, a component in the multi-ingredient formulation Gewodin | Because of its conversion to methamphetamine and amphetamine, which can result in positive drug-testing results, the excretion pattern of these metabolites is critical for proper interpretation of drug-testing results. Multiple doses of famprofazone were administered to healthy volunteers with no previous history of methamphetamine, amphetamine, or famprofazone use. Following administration, urine samples were collected ad lib for nine days, and pH, specific gravity, and creatinine values were determined. To determine the methamphetamine and amphetamine excretion profile, samples were extracted, derivatized, and analyzed by gas chromatography-mass spectrometry (GC-MS). Peak concentrations of methamphetamine ranged from 5327 to 14,155 ng/mL and from 833 to 3555 ng/mL for amphetamine and were reached between 12:22 and 48:45 h post initial dose. There were 15-19 samples per subject that were positive under HHS testing guidelines, with the earliest at 03:37 h post initial dose and as late as 70:30 h post last dose. Methamphetamine and amphetamine were last detected (LOD _> 5 ng/mL) up to 159 h and 153 h post last dose for methamphetamine and amphetamine, respectively. GC-MS was also used to determine the enantiomeric composition of methamphetamine and amphetamine. This analysis revealed both enantiomers were present in a predictable pattern.
Introduction
The challenging task of analyzing and properly interpreting drug-test results for amphetamines depends on a number of factors including an individual's medical history, drug concen- methyl-3-[N-methyl-N-(cz-methylphenylethyl)-aminomethyl]-t-phenyl-3-pyrazolin-3-pyrazoline-5-one) (Gewodin, Geistlich) was obtained from Gewo Chemie GmbH (Baden-Baden, Germany).
Methods

Drug administration and sample collection
Fifty milligrams of famprofazone in the form of two Gewodin tablets was administered twice a day on two consecutive days (effectively at 0, 6, 24, and 30 h after initiation of the study) to healthy adult volunteers (female, ages 25-48) with no previous history of methamphetamine, amphetamine, or famprofazone use. The recommended dosing for an adult is 1-2 tablets up to three times a day as needed (8) . Following the initial dose, individual urine samples were collected ad lib for the next nine days. The urine samples were collected daily and refrigerated at 4~ until analysis. Five subjects were initially enrolled in the study, but one proved unreliable in recording the date and time of sample collection; therefore, results from this subject were not used.
Sample preparation and analysis
A Hewlett-Packard 6890 gas chromatograph (GC) coupled to an HP 5973 mass spectrometer (MS) using a 7683 autoinjector was used for the GC-MS analysis. Samples were analyzed using previously described procedures for quantitative (3, 9) and enantiomer analysis (3, 10) . Sample pH was measured using a Fisher Accumet AR50 pH meter, and the specific gravity using the AO Scientific Refractometer. Creatinine levels were determined by the Wilford Hall Medical Center clinical laboratory.
Extraction procedure
Quantitative analysis. Two-milliliter aliquots, containing 500 ng/mL each of amphetamine-d6 and methamphetamine-dn as internal standards, were extracted by the addition of 0.3 mL 1M NaOH and 5 mL of 1-chlorobutane. The tubes were then shaken for 10 rain at approximately 120 cycles per minute (cpm). If an emulsion was present, samples were centrifuged for 5 rain at approximately 1500 rpm to separate the layers. The organic layer was transferred to a dry, clean, glass screw-top tube and back extracted by addition of 0.15M sulfuric acid (2.0 mL). The tubes were shaken and centrifuged as described. After aspirating the and held for 1 rain. Quantitation was based on a single-point calibration using a 500 ng/mL or 25 ng/mL calibrator, depending on sample concentration. High concentration samples (_> 100 ng/mL) were analyzed using the 500 ng/mL calibrator with controls at 0 ng/mL, 250 ng/mL, and 2500 ng/mL. Control acceptance criteria were as follows: 0 ng/mL control indicated less than the limit of detection (LOD) for analytes; quantitation and ion ratios must be within 20% of calibrator for controls con- taining drug; and low-concentration samples were analyzed using a 25-ng/mL calibrator with controls at 0 ng/mL, 20 ng/mL, and 250 ng/mL. Ions monitored were m/z 240, 118, 91 for amphetamine; 244, 123 for amphetamined6; 254, 210, 118 for methamphetamine; and 213, 260 for methamphetamine-dll. The limits of detection and quantitation (LOQ) are 5 ng/mL for amphetamine and methamphetamine with an upper limit of linearity (ULOL) of 10,000 ng/mL for both amphetamine and methamphetamine. Samples containing analytes at concentrations greater than the ULOL were diluted to bring their measured concentration within the linear range.
Enantiomer analysis. Samples were injected in splitless mode, with the injector and interface temperature at 270~ An HP-1 column (12 m x 0.2-ram i.d., 0.33-pro film thickness, Hewlett-Packard) was used with an initial time of 2 min at 120~ programmed to 185~ at 4~
All sample batches were calibrated with a sample containing 50% of both enantiomers of amphetamine and methamphetamine and analyzed using control samples that contain 0% l-enantiomer plus 100% d-enantiomer of amphetamine and methamphetarnine; and 
Results and Discussion
Following initiation of the study, the first detectable methamphetamine (LOD > 5 ng/mL) and first positive methamphetamine (> 500 ng/mL) were both observed from 02:15 (h:min) to 03:55 h post initial dose (Table I) In all cases, a notable change in drug con-85.94 centration corresponded to a change in the NA pH and/or specific gravity and creatinine. These factors serve as a reminder that methamphetamine and amphetamine concentrations can be dramatically impacted by changes in urine dilution and/or pH. Another important parameter evaluated was the methamphetamine-to-amphetamine ratio over time. Early studies on urinary methamphetamine (12) (13) (14) reported the amount of amphetamine produced from methamphetamine ranged from 2 to 23% of the dose over time. The initial ratio of amphetamine to methamphetamine seen in this study was approximately 20% and increased to as much as 45% in the later samples, which is consistent with the single dose famprofazone data (2, 3) . The single dose studies revealed the concentration of amphetamine excreted initially was approximately 20% of the methamphetamine concentration in all the subjects and increased to as much as 55% that of methamphetamine. Therefore, if under normal conditions, the amphetamine derived from methamphetamine accounts for only up to 23% (14) , amphetamine in this case must be formed from another pathway. It has been shown that amphetamine can be derived from desmethylfamprofazone (15) . Famprofazone must first undergo N-demethylation to form desmethylfamprofazone then N-dealkylation to form amphetamine (Figure 1 ). This pathway would explain the increased percentage of amphetamine. Consistent with results seen in single dose studies (2,3), samples collected shortly after drug administration showed l-methamphetamine to be approximately 70% and increased to nearly 100% over time, whereas/-amphetamine was approximately 50% and increased to as much as 73% over time. As a result of repeated dosing, the change in proportion of enantiomers did not continue to change in a linear fashion until after the last dose was administered. This is consistent with administration of additional drug, which resulted in some variation being observed during the dosing period (0-30 h post initial dose) (Figure 2) .
Most illicit methamphetamine contains only the d-enantiomer, although it is also available as a racemic mixture. After oral ingestion of racemic rnethamphetamine, the excretion of d-to l-methamphetamine was reported to be 50:50 during the first 16 h (12). Because famprofazone results in a higher proportion of l-methamphetamine from the first sample, samples that contain substantially less than 70% l-methamphetamine would not be consistent with famprofazone use. Proportions of greater than 70%, however, could be the result of famprofazone or racemic methamphetamine use.
Previous studies (2, 3, 16, 17) have shown famprofazone is stereoselectively metabolized. The data presented in the present study support this conclusion. Stereoselective metabolism is commonly seen in enzyme catalyzed reactions. If both isomers were metabolized at the same rate, methamphetamine enantiomers would be expected to show a 50:50 ratio. Experimentally, the methamphetamine enantiomer ratio is approximately 70% l-to 30% d-, indicating that l-famprofazone is metabolized to l-methamphetamine at a faster rate than d-famprofazone is metabolized to d-methamphetamine. However, d-methamphetamine is metabolized to d-amphetamine faster than l-methamphetamine metabolizes to/-amphetamine, as shown by the later samples that demonstrated an increase in the proportion of l-methamphetamine over d-methamphetamine.
Differentiation of famprofazone from methamphetamine use could be greatly assisted by monitoring the unique metabolites found following famprofazone administration. However, guidelines set by the Department of Health and Human Services (HHS) state that testing of"other compounds" is prohibited unless there is reasonable suspicion of drug use and the drug in question is classified as Schedule I or II (18) , which eliminates famprofazone and its other metabolites from analysis. In this situation, quantitative and enantiomer analysis alone must be used for interpretation. It is important to remember, however, that the mere presence of these metabolites does not eliminate the possibility of co-administration of methamphetamine or intentional use of famprofazone to mask illicit use. Therefore, quantitative analysis of the metabolites, including amphetamine and methamphetamine, would provide valuable information for interpretation of the results.
Conclusions
Administration of famprofazone results in urinary excretion of methamphetamine and amphetamine in sufficient quantities to produce positive drug testing results. Interpretation of these results is essential in the forensic drug testing community. Detection of methamphetamine and amphetamine in biological samples could be the result of either a pharmaceutical origin or clandestine, illicit origin. Using the combination of drug concentrations and enantiomeric composition will aid in distinguishing famprofazone use from illicit methamphetamine use.
The data presented will provide more insight into the differentiation of famprofazone use from illicit methamphetamine use for an extended period of time, ultimately allowing forensic toxicologists and medical review officers to formulate an educated interpretation regarding positive test results for amphetamine and methamphetamine in urine samples.
